BCMA / Luciferase - CHO Recombinant Cell Line | 79724

BCMA / Luciferase - CHO Recombinant Cell Line | 79724 | Gentaur US, UK & Europe Disrtribition

Category: CAR-T/Cell Line

Application: Use as BCMA-expressing target cells in co-culture assays with BCMA CAR T-cells to screen for BCMA-specific cell killing

Background: B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy not only because of its restricted expression in non-malignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T-cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy the breakthrough designation in treating Multiple Myeloma.

Description: Recombinant CHO-K1 cells constitutively expressing both the human BCMA protein (B-Cell Maturation Antigen or CD269, GenBank accession #NM_001192) and the firefly luciferase reporter. Surface expression of BCMA was confirmed by flow cytometry.

Product Type: Cell Line

Shippement Condition: -80°C